This study was designed to optimize the preparation of delayed-release microcysts containing bone morphogenetic protein 2 (BMP-2) combined with poly(lactic-coglycolic acid) (PLGA) and to investigate their osteogenic properties when combined with rat autologous micromorselized bone and collagen. Rat autologous micromorselized bone, collagen and BMP-2/PLGA delayed-release microcysts were implanted in various combinations into the rat gluteus maximus muscle sack model. The following post-operative measurements were made: general observations of the implant site, histological observations, osteogenesis measurements and alkaline phosphatase activity. Autologous micromorselized bone combined with collagen and BMP-2/PLGA delayed-release microcysts demonstrated significantly superior osteogenic properties than any of the other combinations of these three components. These findings suggest that micromorselized bone combined with collagen and BMP-2/PLGA delayed-release microcysts could reduce the quantity of BMP-2 and autologous bone required for these procedures, making their use feasible in human bone restoration.
Introduction
To improve the osteogenic effects of bone grafts, many studies have been performed showing that ectopic osteogenesis of micromorselized bones is more effective than that of bulk bone. 1 Although bone grafts combined with a growth factor might be more effective at promoting osteogenesis, large quantities of growth factor are required. 2 As bone morphogenetic protein 2 (BMP-2) is very expensive, this would result in high costs for bone grafts, and high-doses Y Ji and GP Xu contributed equally to this study.
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Delayed-release growth factor for bone tissue engineering of BMP-2 are also associated with sideeffects. 3 Growth factors are biological proteins that disseminate rapidly throughout the body, but their biological effects are limited as they typically have short half lives and so are mostly inactive by the time they become involved in bone formation. 4, 5 The effective protection of growth factor activity in vivo is a difficult challenge that must be overcome in order to be able to apply growth factors efficiently in bone tissue engineering.
This study was designed to investigate whether using delayed-release microcyst technology would provide an effective way of delivering growth factor to the bone graft during bone regeneration. In the present study, microcysts were prepared by encapsulating recombinant human BMP-2 (rhBMP-2) in poly(lactic-co-glycolic acid) (PLGA) using the double emulsion method. 6 The effect of delayed-release BMP-2 on ectopic osteogenesis was investigated by transplanting the microcysts combined with autogenous micromorselized bone and collagen into gluteus maximus muscle sacks of Wistar rats. This provided an animal model for the clinical application of grafts containing micromorselized bone, combined with growth factor and collagen, for bone transplantation.
In a previous study, the preparation of BMP-2/PLGA delayed-release microcysts was discussed and the osteogenesis of transplanted micromorselized bone combined with collagen and BMP-2/PLGA delayed-release microcysts was observed. 7 In the present study it was intended to optimize the parameters of BMP-2/PLGA delayedrelease microcysts and to make gross and microscopic observations of the transplantation of micromorselized bone combined with collagen and BMP-2/PLGA delayed-release microcysts with the intention of showing clinical applicability of the protocol. Alkaline phosphatase (ALP) levels and the amount of osteogenesis were also measured to investigate the mechanism involved in the transplantation of micromorselized bone combined with collagen and BMP-2/PLGA delayed-release microcysts.
Materials and methods

EXPERIMENTAL MATERIALS
The PLGA (27 kDa) was obtained from Changchun Institute of Applied Chemistry, Chinese Academy of Sciences (Changchun, China). The rhBMP-2 was obtained from the Chinese Academy of Military Medical Sciences (Beijing, China). Gelatin was purchased from Bio Basic (Markham, Ontario, Canada). Type I collagen, Coomassie G-250 and bovine serum albumin (BSA) were purchased from SigmaAldrich (St Louis, MO, USA). An ALP reagent kit was purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing City, China). A PC-220 magnetic force stirrer was purchased from Corning (Corning, NY, USA). A BioPhotometer ultraviolet spectrophotometer was obtained from Eppendorf (Hamburg, Germany). A Biofuge ® Primo R centrifuge was purchased from Sorvall (Pittsburgh, PN, USA). An E800 light microscope was purchased from Nikon (Tokyo, Japan 
MANUFACTURE OF PLGA MICROCYSTS
Briefly, 1 mg rhBMP-2 in vivo or 2 mg BSA in vitro and gelatin were dissolved and added to 3 ml dichloromethane (DCM) solution that contained the PLGA, prior to dispersal in 150 ml gelatin solution after emulsification. The mixture was stirred at room temperature until the DCM was completely evaporated, and it was then filtered and washed three times with deionized water and freeze-dried overnight. 8 Before packaging, rhBMP-2 was sterilized by 60 Co γ-radiation as described previously. 9
CROSSCUT EXPERIMENT DESIGN
The crosscut experiment design was performed using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Levels of the various parameters in the experiment are shown in Table 1 . The manufacturing methods for the PLGA microcyst were as previously described and the grouping of the various parameter levels was planned. 6 Optimized preparation of microcysts was performed using the method described by Bradford, 10 and the encapsulating rate of microcysts was calculated according to the following equation: encapsulating rate (%) = (actual carrying dosage/theoretical carrying dosage) × 100. 11 Specimens were photographed using a light microscope at 100× magnification and the particle diameter was measured with Image-Pro Plus 5.1 (MediaCybernetics, Bethesda, MD, USA). Scale adjustment was set at each measure. A total of 100 microcysts were sampled from every group of the optimized experiment and the mean values were obtained.
DETERMINATION OF DELAYED RELEASE IN VITRO
The BSA/PLGA microcysts were put into a bag filter, to which was added 3 ml physiological saline. The suspension was placed into a conical flask filled with 54 ml physiological saline, sealed and shaken at 37°C. Samples (3 ml) of physiological saline from outside the bag filter were taken at 2, 4, 
PREPARATION OF AUTOLOGOUS MICROMORSELIZED BONE
Samples of hip bone were obtained from an experimental group of Wistar rats. Soft tissue such as periosteum and cartilage was removed and the bone was placed in 0.9% physiological saline. The bone was then ground with a standard bone mill on a fine setting in normal saline until it reached a particulate size of 0.5 -1.5 mm and was then centrifuged at 1248 g for 5 min to obtain a micromorselized bone pellet.
EXPERIMENTAL RAT MODEL PREPARATION
Wistar rats were randomly divided into four groups of 18 rats in each group, 72 rats in total. A 1-cm incision was made in each thigh of each rat. The skin and subcutaneous tissue were removed to expose the myoideum, and the spatium intermusculare of each thigh was bluntly dissected with a haemostat to form 144 gluteus maximus muscle sack models. In group A, collagen was implanted into the muscle sacks. In group B, collagen and micromorselized bone were implanted. In group C, collagen and rhBMP-2/PLGA delayed-release microcysts were implanted. In group D, collagen, micromorselized bone and rhBMP-2/PLGA delayed-release microcysts were implanted. The amount of collagen used was 50 mg/muscle sack, dissolved in 200 µl of 0.9% physiological saline 5 min before operation, the weight of micromorselized bone was approximately 50 mg after centrifugation, the weight of the PLGA microcysts after freeze-drying was approximately 20 mg and the amount of rhBMP-2 used was 1 mg.
Post-operative observations included recording the presence of wound swelling and secreted material. At the end of the experimental period, the rats were killed and assessed for inflammatory reactions at the site of implantation, osteogenesis and aseptic inflammation.
POST-OPERATIVE ANALYSIS
Three rats were taken from each group on weeks 3, 4 and 5 for gross and histological observations (six gluteus maximus muscle sacks per group at each of weeks 3, 4 and 5). After gross observations had been completed, thigh samples were fixed with 10% neutral formaldehyde, decalcified by ethylenediaminetetraacetic acid, dehydrated by a graded series of ethanol baths, embedded in paraffin, sectioned (5 µm), stained with haematoxylin and eosin, and then examined under a light microscope. The measurement of bone mass required a certain amount of wet weight of callus so it was assessed at week 4 in each group. Levels of ALP were measured at weeks 2 and 4 post-operatively.
STATISTICAL ANALYSIS
Statistical analysis was undertaken using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Data were analysed using multivariate analysis of variance to give the sum of squares of the deviation from the mean and the mean square. A P-value of < 0.05 was considered to be statistically significant.
Results
GENERAL CHARACTERISTICS OF THE MICROCYSTS
The surface of the rhBMP-2/PLGA delayedrelease microcysts was smooth and round ( Fig. 1) , creating spheroplasts with a mean particle diameter of 128.498 ± 36.983 µm. The diameter of the majority of microcysts fell between 100 and 150 µm (Fig. 2) . The mean encapsulation efficiency of the microspheres was 74.018% ± 7.638% (Fig. 3) . After freeze-drying, the microcysts appeared as a fine white powder with no collapse and Y Ji, GP Xu, JL Yan et al. Delayed-release growth factor for bone tissue engineering readily formed a white emulsion after the addition of double-distilled water. Larger microcysts had disadvantages such as reduced dispersal, shapes that were less smooth and round, increased particle diameter and multivesicular bodies. 
DELAYED RELEASE OF BSA IN VITRO
Statistical software was used to analyse the in vitro cumulative BSA release data for PLGA microcysts and obtain the best fit to the cumulative release curve (r = 0.997; Fig.  4 ). The PLGA microcysts released BSA in two stages during the first 264 h, during which time 56.85% of the bag filter contents were released. In the first 24 h, 24.70% of the bag filter contents were released, represented on the cumulative release curve by a steep initial slope indicative of a 'burst' of BSA release (Fig.  4) . During the remaining 240 h, 32.15% of the bag filter contents were released, represented by a shallower slope on the cumulative release curve indicative of a delayed-release of BSA (Fig. 4) .
OPTIMIZED PREPARATION EXPERIMENT
The multiple linear regression models of the encapsulation rate and particle diameter were: Y encapsulation rate = 57.052 -0.233X 1 + 1.913X 2 + 0.675X 3 + 6.503X 4 + 0.592X 5 ; and Y particle diameter = 375.012 -90.506X 1 -71.076X 2 + 53.114X 3 + 17.022X 4 + 1.541X 5 , where: X 1 is stirring rate; X 2 is length of stirrer; X 3 is PLGA/DCM; X 4 is concentration of the continuous phase; and X 5 is concentration of the auxilliary materials. The multiple factor analysis of variance for these are shown in Tables 2 and 3 , respectively. The order of importance of the factors that influenced the encapsulation rate was: continuous phase concentration, size of the stirrer, PLGA/DCM, stirring rate, and concentration of auxiliary materials. Only continuous phase concentration was statistically significant (P = 0.003). The order of importance of the factors that influenced particle diameter was: stirring rate, PLGA/DCM, size of the stirrer, concentration of auxiliary materials, and continuous phase concentration. Only stirring rate, PLGA/DCM, and size of the stirrer were Y Ji, GP Xu, JL Yan et al. Delayed-release growth factor for bone tissue engineering statistically significant (P = 0.001). In addition, the interactions between stirring rate and size of the stirrer (P = 0.005), between the size of the stirrer and PLGA/DCM (P = 0.027), and between all these three factors (P = 0.013) were statistically significant.
ECTOPIC BONE FORMATION IN VIVO
Gross observations
The rats were free to eat and drink, and displayed normal post-operative activities. They presented with differing extents of swelling in the implanted area, which disappeared gradually after about 1 week 
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without any inflammatory exudates. At week 3, the graft in group A rats (collagen implanted into the muscle sacks) could not be palpated, while the grafts in the other three groups could be palpated. When obtaining materials from the area of implantation, the lamellar soft tissue capsule was found to cover the surface of the graft and the surrounding muscle was normal and without purulent exudate. The PLGA microcysts were white with a granular shape and packaged in pieces of tissue.
Histological observations
Collagen was almost totally absorbed in group A (collagen implanted into the muscle sacks) at 3 weeks post-implantation (data not shown), while remnants of collagen were found in the other groups (Fig. 5) . The micromorselized bone had been partially absorbed in group B (collagen and micromorselized bone implanted) and, surrounding the micromorselized bone, the cells had been transformed into cartilage cells and osteogenic cells. The microcysts in group C (collagen and rhBMP-2/PLGA delayedrelease microcysts implanted) had lost their smooth, round shape, their volumes had decreased compared with their original implanted volume, and abundant osteogenic cells were found among the vesicles. The micromorselized bone and microcysts had been partially absorbed in group D (collagen, micromorselized bone and rhBMP-2/PLGA delayed-release microcysts implanted), and were filled with osteogenic and conglobate (globular shaped) cells which were transforming into cartilage cells.
Collagen was difficult to find in group A at 4 weeks post-implantation (data not shown). The micromorselized bone, whose volume had decreased, was absorbed in group B and the surrounding cartilaginous cell mass had increased, containing occasional osteogenic cells and multinucleated osteoclasts (Fig. 6) . In group C, the volume of the microcysts had decreased, their shapes were irregular and the number of osteogenic cells had increased Y Ji, GP Xu, JL Yan et al. Delayed-release growth factor for bone tissue engineering among the microcysts compared with group B. The micromorselized bone and the microcysts were absorbed in group D, with further increased numbers of osteogenic and cartilaginous cells compared with groups B and C.
The volume of the grafts decreased in groups B, C and D at 5 weeks postimplantation (Fig. 7) . Minor microcysts were absorbed and broken into pieces, but the number of surrounding cartilaginous and osteogenic cells had increased and, in group D, their density had also increased.
OSTEOGENESIS MEASUREMENTS
At 4 weeks after the implantations, osteogenesis in group D, defined as bone activity (mg/mg BMP), was 1.9 times than that of group C and 3.2 times that of group B; these differences were statistically significant (P < 0.01; Table 4 ).
ALP MEASUREMENTS
At weeks 2 and 4 after graft implantation, the ALP levels were highest in group D followed by group C then group B, and were lowest in group A (Table 5 ). The levels for 
Discussion
Poly(lactic-co-glycolic acid) has good biocompatibility, can protect proteins from enzymolysis, delays release of drugs and maintains the local concentration of drugs at a sustained level for a long period. 13 These characteristics would suggest that PLGA could be used for the targeted release of growth factors. Using PLGA as a carrier in the present study, optimized preparations of microcysts that had been manufactured with an orthogonal design. The results showed that the surface of PLGA was smooth, round and the spheroplasts had good uniformity. Freezedrying the microcysts resulted in a loose, white, fine powder that readily formed a white emulsion. In vitro studies of BSA release from the PLGA microcysts demonstrated that the amount of BSA released during the 'burst' release period was < 25% of the total. The cumulative release curve was smooth without any large fluctuations (r = 0.997); 56.85% of the BSA was released during the first 11 days. The delayed-release effect of the PLGA microcysts in vitro was clearly demonstrated, which satisfied the initial aims of the experimental design. The methodology used Group A, collagen was implanted into the muscle sacks; group B, collagen and micromorselized bone were implanted; group C, collagen and recombinant human BMP-2 (rhBMP-2)/poly(lactic-co-glycolic acid) (PLGA) delayed-release microcysts were implanted; group D, collagen, micromorselized bone and rhBMP-2/PLGA delayed-release microcysts were implanted. **P < 0.01; † † P < 0.01 versus the other groups for bone weight and bone activity, respectively.
Y Ji, GP Xu, JL Yan et al. Delayed-release growth factor for bone tissue engineering in the present study was suitable for producing PLGA microcysts of 50 -150 µm in diameter that were consistently monovesicular, with a smooth round shape. The mean encapsulation efficiency was 74.018%. Larger microcysts had disadvantages such as reduced dispersal, shapes that were less smooth and round, increased particle diameter and multivesicular bodies. More rigorous equipment is needed to produce smaller microcysts, especially those with diameters measured in nanometres or several micrometres. 14 Micromorselized bone implantation is now widely used in hip joint revision surgery, 15 as well as being the material of choice for the repair of bone defects. Several papers have examined its clinical use. 16, 17 Micromorselized bone possesses several advantages, including: (i) providing close contact with the bone graft bed, which lets the inner cells participate better in osteogenesis; (ii) creating faster blood vessel growth; (iii) releasing more growth factors; (iv) promoting more extensive graft survival; and (v) allowing easier moulding of the bone graft. 1, 7, 18 As the total surface area of morselized bone is very large, many osteocytes survive to play an important role during the early phase of osteogenesis. 1, 19 Collagen is a viscous material with very low antigenicity that plays an adhesive role in bone grafts. It has a high affinity for cells and plays a role in inducing mineral deposition and angiogenesis. 20 Thus, it is able to create a good physical and chemical environment for bone repair. Collagen is not only an adhesive for micromorselized bone, but it is also a good carrier for BMP-2. Collagen enables the uniform distribution of BMP-2 within the graft, maintaining an effective concentration of BMP-2 within the implant for a longer period of time, thereby enhancing the osteogenesis-inducing potential of BMP-2. 21 Moreover, the continuous release of BMP-2 by fibrous connective tissues while they grow within the graft achieves a steady, long-term release. 22 Simple micromorselized bone grafts have the disadvantage of being loose structures that are difficult to shape. A complex of collagen, micromorselized bone and BMP-2/PLGA delayed-release microcysts has a more solid structure but is plastic enough to be shaped easily. The adhesive properties of collagen hold the micromorselized bone and BMP-2/PLGA delayed-release microcysts close together within the bone injury site, allowing the BMP-2 that is released from the microcysts to act directly on the micromorselized bone. Group A, collagen was implanted into the muscle sacks; group B, collagen and micromorselized bone were implanted; group C, collagen and recombinant human BMP-2 (rhBMP-2)/poly(lactic-co-glycolic acid) (PLGA) delayed-release microcysts were implanted; group D, collagen, micromorselized bone, and rhBMP-2/PLGA delayed-release microcysts were implanted. **P < 0.01; † † P < 0.01 versus the other groups at 2 and 4 weeks post-implantation, respectively. 
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This minimizes the risk of BMP-2 inactivation by the surrounding tissue enzymes. The collagen also helps micromorselized bone to act as a scaffold for osteogenesis within the graft. Results from the present study suggest that the lack of aseptic inflammation that was observed was the result of the combination of micromorselized bone and BMP-2/PLGA delayed-release microcysts and collagen, effectively reducing the overaccumulation of PLGA degradation products.
Histological observations from the present study showed that the grafts from animals in groups C (collagen and rhBMP-2/PLGA delayed-release microcysts implanted) and D (collagen, micromorselized bone and rhBMP-2/PLGA delayed-release microcysts implanted) had islands of cartilage cells at week 3 post-implantation and that trabecular bone growth was active, which suggests that BMP-2 was promoting bone formation at an early stage. By week 5 postimplantation, the cartilage and osteogenic cell masses surrounding the micromorselized bone and microcysts in group D became more concentrated, and these were present at significantly higher levels than for groups C and B (collagen and micromorselized bone implanted). Quantitative assay of bone mass showed that, at week 4 post-implantation, bone mass and osteogenic activity in group D were significantly higher than for groups C and B. In group C, which only received collagen and BMP-2/PLGA delayed-release microcysts, the osteogenic activity at week 4 was not particularly prominent. In group B, which only received collagen and micromorselized bone implants, there was evidence of bone formation without BMP-2 stimulation, but osteogenic activity at week 4 was weak.
Activity of ALP reflected bone osteogenic activity when measured at weeks 2 and 4 postimplantation. The ALP level in group C at week 2 was 1.95 times that of group B, but only 1.5 times that of group B at week 4. This indicates that, during the period from postimplantation to week 2, the BMP-2 slowly released by the implants in group C had a higher concentration, and the effect of promoting osteogenesis was more apparent whereas, at week 4, the majority of BMP-2 in the implants was being inactivated, with a gradual decline in osteogenic activity. The activity of ALP in group D was significantly higher than groups A, B and C at both 2 and 4 weeks after implantation. These results suggest that the sustained-release performance of BMP-2/PLGA delayed-release microcysts was stable and reliable, and that the sustained-release of BMP-2 in combination with micromorselized bone and collagen was significantly more conducive to osteogenesis than the other graft combinations.
In conclusion, in an animal model of bone regeneration, the application of bone grafts consisting of collagen and micromorselized bone combined with BMP-2/PLGA delayedrelease microcysts prolonged the release of BMP-2 at the target site, which improved osteogenesis. This method for producing BMP-2/PLGA delayed-release microcysts is stable and repeatable. Thus, it can be suggested that the use of micromorselized bone combined with BMP-2/PLGA delayed-release microcysts and collagen can reduce the quantity of BMP-2 and autologous bone required for these procedures making their use feasible in human bone restoration.
